COPARIME: Pilot Study of a Target Detection of Malignant Melanoma
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Patients at Risk for Melanoma
- Sponsor
- Nantes University Hospital
- Enrollment
- 4118
- Locations
- 1
- Primary Endpoint
- Prevalence ratios between those of the COPARIME cohort and those of the general population.
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
Melanoma is nowadays an important public health problem because its growing incidence. Mass screening for melanoma is not recommended worldwide because of its low cost-effectiveness. Nevertheless targeted screening for patients at high risk for melanoma is promoted. This study is designed to assess the effectiveness and the acceptability of a melanoma targeted screening of melanoma, to estimate the risk function to develop a melanoma among patients at high risk according to the SAMScore and to estimate the ratio cost/ efficacy of the melanoma targeted screening. A cohort of 7700 patients is carried out in 2 departments covered by a registry of cancers. The recruitment had began in April 2011. Patients assessed at high risk according to the SAMScore were proposed a skin examination by their GP every year.
Investigators
Eligibility Criteria
Inclusion Criteria
- •patients more than 18 years old,
- •consulting their GP,
- •assessed at risk for melanoma according to the SAMScore
- •signed the consent.
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Prevalence ratios between those of the COPARIME cohort and those of the general population.
Time Frame: 5 years
Number of melanomas detected / Number of patients at high risk of melanoma defined by our selection tool.
Secondary Outcomes
- Probability to develop a melanoma at one year.(1 years)
- Cost ratio for a screened melanoma.(5 years)